• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Bayer Opens $250M Cell Therapy Manufacturing Facility


Site aims to advance regenerative medicines on a global scale.

Straight Wall Steel Commercial Garage Building. Generative ai. Image Credit: Adobe Stock Images/Scrudje

Image Credit: Adobe Stock Images/Scrudje

Bayer AG announced the official opening of its first cell therapy facility in Berkeley, Calif. with the goal of creating the capacity to bring cell therapies to patients on a global scale. According to a company press release, the $250 million, 100,000-square-foot manufacturing center will supply the material required for late-stage clinical trials and potential commercial launch of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson’s disease.

“Our teams are driving innovation in late-stage development and manufacturing with a goal of bringing transformational cell and gene therapies to patients on a global scale, and this facility will enable us to make it real,” said Jens Vogel, Sr., VP, global head of biotech, Bayer’s pharmaceutical division. “Bayer is collaborating with biotech innovators, academia, and equipment and automation suppliers to establish platforms that would help bring more therapies to patients faster.”

Reference: Bayer Opens First Cell Therapy Manufacturing Facility to Advance Regenerative Medicines on a Global Scale. Business Wire. October 10, 2023. Accessed October 10, 2023. https://www.businesswire.com/news/home/20231009274687/en/Bayer-Opens-First-Cell-Therapy-Manufacturing-Facility-to-Advance-Regenerative-Medicines-on-a-Global-Scale

Related Videos
Related Content